Bioequivalence and Bioavailability Forum

Main page Policy Latest Posts Abbreviations

Oxcarbazepine Tablet Study design [Design Issues]

posted by jag009 – NJ, 2024-07-23 21:50 (693 d 04:48 ago) – Posting: # 24094
Views: 5,055

Hi,

What is your CV for AUC? Like Helmut wrote, Canada requires T/R ratio for Cmax, not 90% CI. Therefore you just need to design and power your study based on CV for AUC.
J

Complete thread:

Oxcarbazepine Tablet Study design AB661 2024-07-13 09:02
- ABE or ABEL for Health Canada Helmut 2024-07-14 12:17
- Oxcarbazepine Tablet Study designjag009 2024-07-23 19:50
  - Health Canada ABEL Helmut 2024-07-24 09:06
  - Oxcarbazepine Tablet Study design AB661 2024-08-24 11:00
    - Oxcarbazepine Tablet Study design Helmut 2024-08-24 12:19

Admin contact
23,654 posts in 4,992 threads, 1,571 registered users;
123 visitors (0 registered, 123 guests [including 9 identified bots]).
Forum time: 02:39 CEST (Europe/Vienna)

Scientists often have a naïve faith that
if only they could discover enough facts about a problem,
these facts would somehow arrange themselves
in a compelling and true solution. Theodosius Dobzhansky

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC

Ing. Helmut Schütz